DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 9, 2009; DOI: 10.1124/dmd.108.026385


0090-9556/09/3707-1427-1433$20.00
DMD 37:1427-1433, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.026385v1
37/7/1427    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Umehara, K.-i.
Right arrow Articles by Kamimura, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umehara, K.-i.
Right arrow Articles by Kamimura, H.

Relationship between Exposure of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a "Funny" If Current Channel Inhibitor, and Heart Rate Reduction in Tachycardia-Induced Beagle Dogs

Ken-ichi Umehara, Kouichi Wada, Kiyoshi Noguchi, Takafumi Iwatsubo, Takashi Usui, and Hidetaka Kamimura

Drug Metabolism Research Laboratories (K.U., K.N., T.I., T.U., H.K.) and Applied Pharmacology Research Laboratories (K.W.), Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan

(–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel "funny" If current channel (If channel) inhibitor, is developed as a treatment for stable angina and atrial fibrillation. In this study, the pharmacokinetic/pharmacodynamic (PK/PD) relationship after intravenous administration of YM758 to tachycardia-induced dogs was investigated and described based on the simplified compartment model. The PK of YM758 in dogs did not differ between the nontreated and tachycardia-induced groups. A drug-induced reduction in heart rate (HR) was clearly observed, and the half-life of the duration of the effect (approximately 4.0 h) was longer than that of the plasma concentration of the unchanged drug. The fitting and simulation procedure from the PK/PD relationship between the time profiles for YM758 plasma concentration and HR reduction had an ECe50 value (YM758 concentration in the effective compartment resulting in a 50% decrease of the maximum effect) of 6.0 ng/ml, which did not agree with the results of the in vitro experiment using right atria isolated from guinea pigs (EC30, 70.4 ng/ml). In addition, in the in vitro experiments, YM758 metabolites had a weak inhibitory effect, if any, on the spontaneous beat rate of the right atria from guinea pigs. These data, along with the previous finding that YM758 and its metabolites are eliminated rapidly from rat hearts, indicate that the duration of the pharmacological effect of YM758 (compared with the rapid elimination of the plasma drug concentration) may be the result of strong binding and/or slower dissociation of YM758 in the If channel. Such PK/PD analyses allow the pharmacological profiles of many drugs, especially cardiovascular drugs, to be more readily understood and better predicted during the clinical stages.


Address correspondence to: Ken-ichi Umehara, Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan. E-mail: kenichi.umehara{at}jp.astellas.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K.-i. Umehara, N. Nakada, K. Noguchi, T. Iwatsubo, T. Usui, and H. Kamimura
Investigation of Long-Term Retention of Unchanged (-)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide, A Novel "Funny" If Current Channel Inhibitor, and Its Metabolites in the Eyeball and Thoracic Aorta of Rats
Drug Metab. Dispos., November 1, 2009; 37(11): 2137 - 2144.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.